TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04181684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procedure: LITT
Description: This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypo-Fractionated Radiation Therapy
Description: Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
Study: NCT03500913

Intervention type: DRUG
Intervention: Growth Hormone
Description: Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
Study: NCT02337751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVP-1012 1mg
Description: TVP-1012 1mg Tablets
Study: NCT00369473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 108
Description: 125 mg via SC (subcutaneous) injection every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 108
Description: 250 mg via SC (subcutaneous) injection every 4 weeks
Study: NCT02793076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bollywood Dance
Description: 8 week Bollywood Dance Program
Study: NCT00832182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin NPH
Description: Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
Study: NCT05569031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: patients with tramadol abuse will use venlafaxine for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine
Description: patients with tramadol abuse will use lofixidine for 10 days.
Study: NCT01006473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Study: NCT04866251

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gag reflex test; assessment of Mallampati Score
Description: Testing of gag reflex Assessment of Mallampati Score

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gag reflex test; assessment of Mallampati Score
Description: Testing of gag reflex Assessment of Mallampati Score

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gag reflex test; assessment of Mallampati Score
Description: Testing of gag reflex Assessment of Mallampati Score

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gag reflex test; assessment of Mallampati Score
Description: Testing of gag reflex Assessment of Mallampati Score

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gag reflex test; assessment of Mallampati Score
Description: Testing of gag reflex Assessment of Mallampati Score

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gag reflex test; assessment of Mallampati Score
Description: Testing of gag reflex Assessment of Mallampati Score

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gag reflex test; assessment of Mallampati Score
Description: Testing of gag reflex Assessment of Mallampati Score
Study: NCT01009580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
Study: NCT04754204

Intervention type: DEVICE
Intervention: Arrhythmia Management System (AMS)
Description: AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity and body posture.
Study: NCT03187574

Intervention type: DEVICE
Intervention: Elevate Ant™
Description: Surgery with Elevate Ant™
Study: NCT03117751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or by subcutaneous injection (SQ).
Study: NCT03187574

Intervention type: DEVICE
Intervention: Perigee™
Description: Surgery with Perigee™
Study: NCT04000360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Aerobic Exercise
Description: The home-based exercise group will receive a Peloton indoor cycle delivered to their home and a heart rate monitor strap. Participants will be asked to cycle 3x/week for 12 months on their bike with their heart rate monitor at an aerobic intensity between 60-80% of heart rate reserve with a target cadence between 80-90 revolutions per minute (RPMs). Additionally, participants (both groups) will receive activity monitors to monitor their daily activity levels.
Study: NCT02087709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-calorie diet
Study: NCT02715791

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TAP-HC-DM
Description: Patients randomized to the intervention group will complete the Healthy Lifestyle App modules. Their results will create a report with a suggested list of tip sheets that patients, volunteers, and clinics will see.~Patients will also be encouraged to access the McMaster PHR in order to track their health, and communicate with volunteers or the clinic.~Volunteer health connectors will connect with patients at least weekly, by phone, McMaster PHR message, or in person (depending on patient preference). They will be motivating, providing tip sheets or other education, doing tech support, providing community resources, and building a volunteer-patient relationship with the client.~Clinicians will see and triage the reports, and may follow up on various aspects identified.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients randomized to the control group will receive usual care and upon the end of the intervention arm of the study will receive the TAPESTRY-HC-DM intervention as detailed in the intervention group.
Study: NCT01439360

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix Junior
Description: Intramuscular injection administered to subjects aged 12 months or older

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: Intramuscular injection administered to subjects less than 12 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax/ProVarivax
Description: Intramuscular injection administered to subjects more than 12 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varilrix
Description: Subcutaneous injection administered to subjects more than 12 months of age
Study: NCT06610292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication reconciliation services
Description: Upon admission, information about patients Best Possible Medication History (BPMH) was extracted. Information on current medications, both regular and as-needed, was also recorded. All data were cross-referenced with the electronic records and verified through patients or caregivers interviews to create a comprehensive medication list.~Then, comparison was conducted between standard care medication list and Pharmacist-led medication reconciliation list to identify any possible medication discrepancies. Also, during hospital stay and upon discharge emerging medication discrepancies were assessed and resolved.~Moreover, the impacts on healthcare resources utilization within 30 days post-discharge was measured. This includes evaluating hospital re-admissions, emergency department visits, and the occurrence of any adverse drug events (ADEs).
Study: NCT00812331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.
Study: NCT03117751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or by subcutaneous injection (SQ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or by subcutaneous injection (SQ).
Study: NCT00812331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.
Study: NCT02199743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone
Description: Compare to haloperidol and perphenazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone
Description: Compare to haloperidol and perphenazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone
Description: Compare to haloperidol and perphenazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Compare to lurasidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Compare to lurasidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Compare to lurasidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Description: Compare to lurasidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Description: Compare to lurasidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Description: Compare to lurasidone
Study: NCT03117751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or by subcutaneous injection (SQ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or by subcutaneous injection (SQ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO.
Study: NCT03289429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin in a dose of 80 mgs, twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate: ( 3 grams dissolved in 100 mL of isotonic saline to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravenous placebo
Description: 100 mL of isotonic saline (to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intravenous placebo
Description: 100 mL of isotonic saline (to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
Study: NCT03289429

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: tablets placebo
Description: Placebo tablets: twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tablets placebo
Description: Placebo tablets: twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
Study: NCT01234077

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: CPC M1
Description: CPC M1
Study: NCT02877238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane plus remote ischemic preconditioning
Description: Inhalational anesthesia (Sevoflurane) in addition to remote ischemic preconditioning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total intravenous anesthesia plus remote ischemic preconditioning
Description: Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
Study: NCT02455154

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole endocrine therapy for 2.5mg qd po.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole endocrine therapy for 2.5mg qd po.
Study: NCT03117751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi (recombinant)-rywn
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi (recombinant)-rywn
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi (recombinant)-rywn
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.
Study: NCT00003127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: 740 mg/m2 IV, Day 1, q 28 days X 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: target AUC=6, IV Day 1, q 28 days X 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175 mg/m2, IV, Day 1 q 28 days X 6 cycles
Study: NCT01831024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dignicap System
Description: The DigniCap™ System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap™), the neoprene outer cap (DigniTherm™), and the liquid coolant (DigniCool). DIGNISTICK™ is prepared to log data from a treatment when inserted in the slot. DIGNICARD™ is a key card which has to be inserted in order to start a treatment.
Study: NCT03729115

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Patients will have MRI scans every 6 months.
Study: NCT00023959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03804840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04247139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kefir
Description: commercial versus traditional kefir

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kefir
Description: commercial versus traditional kefir
Study: NCT02257138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study: NCT02194387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Record dietary intake 4-7 days per week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Record dietary intake 1 day per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive email coaching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Participate in social networking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone coaching

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive text messages
Study: NCT02939807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC294640
Description: ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.~ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days.
Study: NCT02455154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole endocrine therapy for 2.5mg qd po.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zhongyaofufang
Description: Traditional Chinese Medicine for patients with Osteoporosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xianlinggubao
Description: Traditional Chinese Medicine for patients with Osteoporosis
Study: NCT03911505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cipaglucosidase Alfa
Description: Enzyme Replacement Therapy via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat
Description: Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat(AT2221)
Study: NCT00563056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutiform

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flixotide plus Foradil
Study: NCT01616966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Maintenance of anesthesia with sevoflurane 1.0 Vol%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Maintenance of anesthesia with propofol
Study: NCT01076478

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cilostazol
Description: 100 mg, 200mg tablet Cilostazol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: 100 mg, 200mg tablet Cilostazol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: 100 mg, 200mg tablet Cilostazol
Study: NCT03454763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRRT every 5 weeks
Description: PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRRT every 8-10 weeks
Description: PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles